I-Chow Hsu, MD

Radiation oncologist

Dr. I-Chow (Joe) Hsu is a radiation oncologist with special expertise in brachytherapy, a form of radiotherapy where a radioactive source is placed inside or next to the area requiring treatment such as localized prostate cancer. Hsu has special research interests in the application of brachytherapy and hyperthermia in genitourinary and gynecologic cancers. He is an active member of numerous professional medical societies including the American Society for Therapeutic Radiology, American Brachytherapy Society and Society for Thermal Medicine. He also chairs the brachytherapy committee of the Radiation Therapy Oncology Group.

Hsu earned a medical degree at the Johns Hopkins School of Medicine and completed a residency in radiation oncology at Columbia-Presbyterian Medical Center in New York. He is a professor of radiation oncology at the University of California, San Francisco. Hsu is certified in radiation oncology by the American Board of Radiology.

Clinics

Radiation Oncology at Mission Bay
1825 Fourth St., First Floor, Room M2267
San Francisco, CA 94158
Phone: (415) 502-7222
Fax: (415) 353-9884

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Conditions & Treatments

Board Certification

Radiation Oncology, American Board of Radiology

Academic Title

Professor

More about I-Chow Hsu

Additional Languages

Chinese
Mandarin

Education

John Hopkins School of Medicine 1991

Residencies

San Bernadino Medical Center, Transitional Intern 1992

Fellowships

Columbia-Presbyterian Medical, Radiation Oncology 1995

Selected Research and Publications

  1. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72.
  2. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8.
  3. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Nov-Dec; 14(6):795-800.
  4. Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JAM, Sethi RA, Chan JK, Hsu IC. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1093-1100.
  5. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20.
  6. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
  7. Cunha JA, Mellis K, Sethi R, Siauw T, Sudhyadhom A, Garg A, Goldberg K, Hsu IC, Pouliot J. Evaluation of PC-ISO for customized, 3D Printed, gynecologic 192-Ir HDR brachytherapy applicators. J Appl Clin Med Phys. 2015 Jan 08; 16(1):5168.
  8. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
  9. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR appropriateness CriteriaŽ Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
  10. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
  11. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
  12. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness CriteriaŽ Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
  13. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
  14. Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51.
  15. Salgaonkar VA, Prakash P, Rieke V, Ozhinsky E, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys. 2014 Mar; 41(3):033301.
  16. Nattagh K, Siauw T, Pouliot J, Hsu IC, Cunha JA. A training phantom for ultrasound-guided needle insertion and suturing. Brachytherapy. 2014 Jul-Aug; 13(4):413-9.
  17. Thomadsen BR, Erickson BA, Eifel PJ, Hsu IC, Patel RR, Petereit DG, Fraass BA, Rivard MJ. A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: executive summary. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):65-70.
  18. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014 Feb 02; 9:42.
  19. Hsu IC, Hunt D, Straube, W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
  20. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.